Live Biotherapeutics Products and Microbe CDMO Market - Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028

The Global Live Biotherapeutics Products (LBPs) Market is anticipated to rise at a high CAGR during the forecast period, 2024-2028. Growing prevalence of certain chronic diseases such as cardiovascular diseases, diabetes, chronic respiratory diseases, cancer, and chronic kidney disease across various countries are expected to register a lucrative growth to global live biotherapeutics products and microbe CDMO market in the forecast period. Moreover, growing preference of people around the world towards personalized medicines for physical and mental health are expected to propel the growth of live biotherapeutics products and microbe CDMO market in upcoming years.

Live Biotherapeutics Products (LBPs) are a type of therapeutic product that utilize living microbes to treat various medical conditions. Some of the commonly available live biotherapeutics products available in the market includes Lactobacillus acidophilus, Bifidobacterium lactis, Streptococcus thermophilus, Saccharomyces boulardii, and Escherichia coli Nissle. These microbes, such as bacteria or yeast, are typically found in the gut microbiome and play a critical role in maintaining human health. LBPs work by introducing these microbes into the body in a controlled manner to restore or enhance their function.

A Microbial Contract Development and Manufacturing Organization (CDMO) is a company that specializes in the development and manufacturing of microbial-based products, including live biotherapeutics product. Microbe CDMOs can provide a range of services, including strain development, fermentation optimization, downstream processing, and quality control. CDMO activities can be broadly categorized into three categories such as product development, manufacture of active pharmaceutical ingredients (API), and manufacture of finished dosage forms (FDF). There are around 500 Contract Development and Manufacturing Organization established in the world. Among them, Switzerland-based Lonza is the leading CDMO industry functioning across the world.

Increasing Prevalence of Chronic Diseases

Chronic diseases are defined broadly as conditions that progress slowly and persist over an extended period. Some of the major risk factors which lead to the development of chronic illness inside human body include intake of unbalanced diet, consumption of alcohol, smoking cigarettes, physical inactivity, and others. Cardiovascular diseases, Cancer, and diabetes are three most prevailing chronic diseases in the world which are thereby increasing the mortality of every country in the forecast period. According to the report published by Pan American Health Organization (PAHO) in 2019, Ischemic heart disease accounted for 73.6 deaths per 100,000 population in the world, followed by stroke with 32.3 deaths, other circulatory diseases with 14.8 deaths, hypersensitive heart disease with 10.6 deaths, cardiomyopathy, myocarditis, and endocarditis with 5.1 deaths and rheumatic heart disease with 0.7 deaths of total population across the world. After cardiovascular diseases, cancer has been reported as second major reason behind the growing mortality rate of various developing countries across the world. As per the report published by World Health Organization (WHO) in 2022, it has been observed that lung cancer has been the most prominent type of cancer prevailing across the world accounting for 1.80 million deaths, followed by 9,16,000 deaths caused by colon and rectum cancer, 8,30,000 deaths due to liver cancer, 7,69,000 deaths by stomach cancer and 6,85,000 deaths caused by breast cancer. Live biotherapeutic products are designed to modulate the gut microbiome which plays a major role in maintaining a healthy immune system and preventing chronic diseases. Moreover, microbe CDMOs provide customized solutions for the development, manufacturing, and scale-up of microbial products for clinical trials and commercial use. Other health problems which can affect the human body along with prevalence of chronic diseases are expected to propel the growth of global biotherapeutics products and microbe CDMO market in the forecast period.

Rise in Demand for Personalized Medicines

The growing demand for personalized medicines is indeed a significant driver of the global biotherapeutics products and microbe CDMO (Contract Development and Manufacturing Organization) market. Biotherapeutics products, including personalized medicines, are a major growth area of pharmaceutical industry. These products are derived from biological sources, such as living cells, and can be used to treat a wide range of diseases, including cancer, autoimmune disorders, and genetic diseases. Moreover, microbe CDMOs are specialized in the development and manufacturing of biotherapeutics products, including personalized medicines, using microbial systems such as bacteria, yeast, and fungi. These CDMOs offer a range of services, including cell line development, process development, analytical development, and manufacturing. The growing demand for personalized medicines has led to an increase in the demand for these services which are further projected to register an impressive growth to Global Biotherapeutics Products and Microbe CDMO market in upcoming years.

Market Segmentation

Global live biotherapeutics products and microbe CDMO market is segmented based on application, product, type of formulation, scale of operation, company, and region. In terms of application, the live biotherapeutics products and microbe CDMO market is categorized into C.difficle, Crohns disease, IBS, diabetes, and others. Based on product, the global live biotherapeutics products and microbe CDMO market is fragmented into APIs and FDFs. Based on type of formulation, the market is segmented into solid formulations, oral liquids, injectables, and others. Based on scale of operation, the global live biotherapeutics products and microbe CDMO market is fragmented into preclinical scale operations, clinical scale operations, and commercial scale operations.

Market Players

Arranta Bio Holdings LLC., 4D Pharma plc., Cerbios-Pharma S.A., Biose Industrie, Assembly Biosciences, Inc., Wacker Chemie AG, Quay Pharmaceuticals Ltd., Bacthera AG, LONZA, and Inpac Probiotics are the major players of global live biotherapeutics products and microbe CDMO market.

Report Scope

In this report, Global Live Biotherapeutics Products and Microbe CDMO Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Live Biotherapeutics Products and Microbe CDMO Market, by Application:

• C.difficle
• Crohns disease
• IBS
• Diabetes
• Others

Live Biotherapeutics Products and Microbe CDMO Market, by Product:

• APIs
• FDFs

Live Biotherapeutics Products and Microbe CDMO Market, by Type of Formulation:

• Solid Formulations
• Oral Liquids
• Injectables
• Others

Live Biotherapeutics Products and Microbe CDMO Market, by Scale of Operation:

• Preclinical Scale Operations
• Clinical Scale Operations
• Commercial Scale Operations

Live Biotherapeutics Products and Microbe CDMO Market, by region:

• North America
• Asia-Pacific
• Europe
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Live Biotherapeutics Products and Microbe CDMO Market

Available Customization

The following customization option is available based on your specific needs: Detailed analysis and profiling of additional market players (up to five).


This product will be delivered within 1-3 business days.